Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 18/20 | 0.68 |
| ▸ | AURKA | O14965 | 10/20 | 0.66 |
| ▸ | LCK | P06239 | 10/20 | 0.66 |
| ▸ | TEK | Q02763 | 10/20 | 0.66 |
| ▸ | MET | P08581 | 8/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.66 |
| ▸ | LYN | P07948 | 2/20 | 0.64 |
| ▸ | FLT1 | P17948 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753804 | 0.93 | PDGFRA (0.80) | PDGFRAKDRAURKALCKTEK | |
| SCHEMBL7784223 | 0.91 | PDGFRA (0.66) | PDGFRAKDRAURKALCKTEK | |
| SCHEMBL3747657 | 0.89 | PDGFRA (0.85) | PDGFRAKDRAURKALCKTEK | |
| SCHEMBL3758508 | 0.89 | KDR (0.65) | PDGFRAKDRAURKALCKTEK | |
| SCHEMBL3754543 | 0.89 | PDGFRA (0.65) | PDGFRAKDRAURKALCKTEK | |
| SCHEMBL4548840 | 0.87 | KDR (0.80) | KDRAURKALCKTEKMET | |
| SCHEMBL7783895 | 0.85 | HDAC2 (0.59) | PDGFRAKDRAURKALCKTEK | |
| SCHEMBL2748059 | 0.84 | KDR (0.79) | KDRAURKALCKTEKMET | |
| SCHEMBL7788968 | 0.84 | PDGFRA (0.76) | PDGFRAKDRAURKALCKTEK | |
| SCHEMBL3747863 | 0.83 | KDR (0.64) | PDGFRAKDRAURKALCKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211901-B2 | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2012-07-03 | — | — | US | disclosed |
| US-8211901-B2 | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2012-07-03 | — | — | US | disclosed |
| US-8211901-B2 | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2012-07-03 | — | — | US | disclosed |
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC5 | PDGFRA 1852/4885KDR 2729/4885AURKA 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.